This site use cookies
This site uses cookies that help us to improve our site by providing analytics and usage information. By clicking accept or continuing to use this site you are agreeing to our cookie policy. If you do not agree, please close this notice. Learn more

Watch Exonate’s principal scientist, Dr Jennifer Batson interviewed for Bermuda TV

Posted on 27 Feb 2018

Watch Dr Jennifer Batson as she was interviewed for Bermuda TV during The Bermuda Principles Impact on Splicing 2nd Annual conference on Saturday 24th February 2018.

During session 13 ‘Commercialisation of University Research’, Dr Batson presented ‘Developing inhibitors of VEGF-A alternative splicing into a clinical candidate to deliver a paradigm shift in the treatment of retinal vascular diseases’.

In this interview, she speaks of Exonate’s mission to introduce a revolutionary, game changing eye drop for the treatment of retinal vascular diseases including wet AMD and diabetic macular oedema (DME).  Exonate has developed small molecules that inhibit production of pro-angiogenic VEGF through selective inhibition of serine/threonine-protein kinase (SRPK1) – mediated VEGF splicing.  Already, these inhibitors have demonstrated superior efficacy as topical agents in preclinical models of wAMD.  Dr Batson discusses the exciting journey from basic understanding of VEGF-A splicing mechanisms to candidate therapeutic nomination.

Watch here

Categories related to this article

In the press